CMX001: Phase II started

Chimerix began a double-blind, placebo-controlled, dose-escalation, U.S. Phase II trial to evaluate oral CMX001 in about 120 patients. Initial dosing of CMX001 will begin at 40 mg once weekly for 13 w...